AURKA and central nervous system cancer: To analyse the requirement for AurA activity in the two populations, we treated stem and differentiated glioma cells with the AurA inhibitor MLN8237, using low dose levels that only had subtle effects on overall AurA kinase activity (supplementary Fig. S2C).